PRM — Big Pharma Split Share Price
Last trade - 00:00- CA$13.30m
- -CA$12.91m
- CA$0.66m
- 76
- 81
- 40
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.53 | ||
| Price to Tang. Book | 0.53 | ||
| Price to Free Cashflow | 7.77 | ||
| Price to Sales | 20.12 | ||
| EV to EBITDA | -962.52 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 0.05% | ||
| Return on Equity | -2.1% | ||
| Operating Margin | 2.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.79 | 5.62 | 4.03 | 0.54 | 0.66 | n/a | n/a | -19.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -51.51 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Big Pharma Split Corp. (the Fund) is a Canada-based investment fund. The Fund invests, with equal weighting as a percentage of net asset value of the Fund, in equity securities of 10 issuers, primarily from the pharmaceutical sector. The Fund’s investment objective is to provide holders of preferred shares a fixed cumulative preferential quarterly cash distributions in the amount of $0.125 per Preferred share ($0.50 per annum or 5.0% per annum on the issue price of $10.00 per Preferred share) and to return the original issue price of $10.00 to holders on the maturity date, and holders of Class A shares a regular monthly noncumulative cash distributions targeted to be $0.1031 per Class A share representing a yield on the issue price of the Class A shares of 8.25% per annum on the issue price of $15.00 per Class A Share and to provide holders with the opportunity for growth in the net asset value per Class A share. Its portfolio manager is Harvest Portfolios Group Inc.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 15th, 2017
- Public Since
- November 23rd, 2017
- Sector
- Collective Investments
- Industry
- Financials
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 1,157,338
- Address
- 610 Chartwell Road, Suite 204, OAKVILLE, L6J 4A5
- Web
- Phone
- +1 4166494541
- Auditors
- PricewaterhouseCoopers LLP
Latest News for PRM
Upcoming Events for PRM
Dividend For PRM.TO - 0.1031 CAD
Similar to PRM
2028 Investment Grade Bond Trust
Toronto Stock Exchange
abrdn Asia-Pacific Income Fund VCC
Toronto Stock Exchange
Brompton Energy Split
Toronto Stock Exchange
Brookfield Global Infrastructure Securities Income Fund
Toronto Stock Exchange
Canadian Banc
Toronto Stock Exchange
FAQ
As of Today at 19:34 UTC, shares in Big Pharma Split are trading at CA$11.49. This share price information is delayed by 15 minutes.
Shares in Big Pharma Split last closed at CA$11.49 and the price had moved by -14.89% over the past 365 days. In terms of relative price strength the Big Pharma Split share price has underperformed the Toronto Stock Exchange 300 Composite Index by -24.33% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Big Pharma Split dividend yield is 10.77% based on the trailing twelve month period.
Last year, Big Pharma Split paid a total dividend of CA$1.24, and it currently has a trailing dividend yield of 10.77%.Looking ahead, shares in Big Pharma Split are due to go ex-dividend on 2025-04-30 and the next dividend pay date is 2025-05-09.
Big Pharma Split are due to go ex-dividend on 2025-04-30 and the next dividend pay date is 2025-05-09. The historic dividend yield on Big Pharma Split shares is currently 10.77%.
To buy shares in Big Pharma Split you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$11.49, shares in Big Pharma Split had a market capitalisation of CA$13.30m.
Here are the trading details for Big Pharma Split:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: PRM
Based on an overall assessment of its quality, value and momentum Big Pharma Split is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Big Pharma Split. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -17.05%.
As of the last closing price of CA$11.49, shares in Big Pharma Split were trading -15.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Big Pharma Split PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$11.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Big Pharma Split's directors